This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novartis, Pfizer and Bayer
by Zacks Equity Research
Big Pharma faces tariff risks, patent cliffs, and regulatory pressure, but innovation and strong pipelines keep Eli Lilly, J&J, Novartis, Pfizer, and Bayer in focus.
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
J&J Gains FDA Approval for Inlexzoh, Strengthens Pipeline Momentum
by Kinjel Shah
J&J secures FDA approval for Inlexzoh, which boosts its Innovative Medicine pipeline and reinforces long-term growth momentum.
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
by Ahan Chakraborty
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Will Merck's Cost Cuts and New Drug Approvals Ease Headwinds?
by Kanishka Das
MRK expects strong Keytruda sales, new drug launches and $3B in planned cost savings to offset pressure from declining Gardasil sales and other headwinds.
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
by Ahan Chakraborty
Alnylam's strong drug sales and advancing partnerships with Regeneron and Roche highlight key growth drivers in the quarters ahead.
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
by Kinjel Shah
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
J&J vs. AbbVie: Which Healthcare Powerhouse Is Better Positioned?
by Kinjel Shah
ABBV and JNJ face patent cliffs but show resilience with strong pipelines, acquisitions and promising growth drivers.
Pfizer's 6.9% Yield & Bullish Signal: A Prime Buying Opportunity?
by Tirthankar Chakraborty
Pfizer's strong Q2 results, high dividend yield, and bullish chart fuel optimism despite patent losses and rising competition.
J&J Gears Up for Some Key New Drug Approvals and Launches
by Kinjel Shah
JNJ believes 10 of its new products and pipeline candidates can deliver peak sales of $5 billion, including Talvey, Tecvayli, Imaavy, Caplyta and others.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
by Ahan Chakraborty
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
Pfizer's Golden Cross Signals Strength: How to Play the Stock
by Kinjel Shah
Pfizer trades above key SMAs with a golden cross, while new drugs and cost cuts drive growth despite looming headwinds.
Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.
FDA Approves Updated COVID-19 Vaccines but With Restrictions
by Zacks Equity Research
FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.
MRK, Daiichi Begin Phase III Breast Cancer Study With ADC Candidate
by Zacks Equity Research
Merck and Daiichi Sankyo begin dosing in the phase III HERTHENA-Breast04 study on patritumab deruxtecan in certain breast cancer patients.
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
by Ahan Chakraborty
ALNY's Amvuttra revenues surge with 89% sales growth in H1 and a key label expansion, but faces tough competition in the ATTR-CM market.
Can Pfizer's Cost Cuts and New Drugs Offset Upcoming Headwinds?
by Kinjel Shah
Pfizer braces for patent losses, IRA pressure and COVID uncertainty, but cost cuts and key drugs may still support profit growth.
Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
by Ekta Bagri
Bristol Myers leans on Eliquis and surging Camzyos sales to offset looming generics, while its pipeline candidate milvexian readouts are near.
LLY vs. PFE: Which Pharma Giant Is the Better Pick for Investors?
by Kinjel Shah
Pfizer's cost cuts, new products and cheaper valuation give it an edge over Eli Lilly despite LLY's strong GLP-1 momentum.
GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU
by Zacks Equity Research
Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.
Top Analyst Reports for NVIDIA, Cisco & Linde
by Mark Vickery
NVIDIA, Cisco and Linde post strong gains as analysts spotlight AI growth, software expansion and industrial gas leadership.
AbbVie Pins Hopes on Rinvoq to Drive Next Phase of Growth
by Kanishka Das
ABBV posts strong phase III alopecia areata data from the second study on Rinvoq. The drug hit $3.7B in H1 sales and is expected to further drive growth in H2.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
ABBV's Improving Oncology Sales Poise It Well for Long-Term Growth
by Kinjel Shah
AbbVie's oncology sales climbed 4.2% in H1 2025 as new drugs offset Imbruvica declines, strengthening its long-term growth outlook.